Nicholson R I, Gotting K E, Gee J, Walker K J
Tenovus Institute for Cancer Research, University of Wales College of Medicine, The Heath, Cardiff.
J Steroid Biochem. 1988;30(1-6):95-103. doi: 10.1016/0022-4731(88)90081-7.
The proliferative actions of a series of antioestrogens on the development of the second thoracic mammary gland of ovariectomized immature Sprague-Dawley rats have been investigated. Evidence is presented that shows trans-tamoxifen, LY 117018 and LY 139481, like oestradiol-17 beta and cis-tamoxifen, promote full mammary gland ductal development and induce a high rate of cell proliferation in the undifferentiated epithelial cells of the terminal end buds, the main growth region for ductal growth. Conversely, ICI 164,384, a new antioestrogen, is without effect on ductal elongation. In vivo exposure of trans-tamoxifen and LY 117018 treated glands in medically castrated animals to the carcinogen DMBA, results in a high rate of mammary tumour development. Indeed, the actions of these so-called antioestrogens are equivalent to those observed in oestradiol-treated rats.
一系列抗雌激素对去卵巢未成熟斯普拉格-道利大鼠第二胸段乳腺发育的增殖作用已得到研究。有证据表明，反式他莫昔芬、LY 117018和LY 139481与雌二醇-17β和顺式他莫昔芬一样，能促进乳腺导管充分发育，并在终末芽的未分化上皮细胞（导管生长的主要生长区域）中诱导高细胞增殖率。相反，新型抗雌激素ICI 164,384对导管伸长没有影响。在医学去势动物中，经反式他莫昔芬和LY 117018处理的腺体在体内暴露于致癌物DMBA后，会导致乳腺肿瘤的高发生率。事实上，这些所谓的抗雌激素的作用与在经雌二醇处理的大鼠中观察到的作用相当。
